MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma.

[1]  Shaochong Zhang,et al.  Megakaryocytes Mediate Hyperglycemia-Induced Tumor Metastasis , 2021, Cancer Research.

[2]  [Clinical practice guideline for lympoma in China (2021 Edition)]. , 2021, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[3]  Yihai Cao,et al.  Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism , 2021, Gut.

[4]  I. Lossos,et al.  Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. , 2020, Blood.

[5]  De-Pei Wu,et al.  MYC-regulated lncRNA NEAT1 promotes B cell proliferation and lymphomagenesis via the miR-34b-5p-GLI1 pathway in diffuse large B-cell lymphoma , 2020, Cancer Cell International.

[6]  W. Cho,et al.  Mechanisms and Treatment Progress of Rituximab-Resistance in Diffuse Large B-cell Lymphoma. , 2019, Current cancer drug targets.

[7]  Yihai Cao,et al.  Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance. , 2018, Cell metabolism.

[8]  D. Bu,et al.  IP3R-Grp75-VDAC1-MCU calcium regulation axis antagonists protect podocytes from apoptosis and decrease proteinuria in an Adriamycin nephropathy rat model , 2018, BMC Nephrology.

[9]  T. Waldmann,et al.  Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma , 2018, Proceedings of the National Academy of Sciences.

[10]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[11]  G. Salles,et al.  Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience , 2017, Advances in Therapy.

[12]  M. Manz,et al.  Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth , 2017, Proceedings of the National Academy of Sciences.

[13]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[14]  B. Coiffier,et al.  Diffuse large B-cell lymphoma: R-CHOP failure-what to do? , 2016, Hematology. American Society of Hematology. Education Program.

[15]  Yihai Cao,et al.  Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism , 2016, Nature Communications.

[16]  N. Samani,et al.  The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages , 2016, Nature Communications.

[17]  G. Lenz,et al.  CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. , 2016, Blood.

[18]  R. Samaka,et al.  The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients , 2015, Analytical cellular pathology.

[19]  M. Michalak,et al.  Ca(2+) homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling. , 2015, Biochemical and biophysical research communications.

[20]  D. Krappmann,et al.  Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies , 2014, Oncogene.

[21]  Baocun Sun,et al.  Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues , 2013, Proceedings of the National Academy of Sciences.

[22]  W. Guo,et al.  Glucose-regulated protein 75 overexpression attenuates ionizing radiation-mediated injury in PC12 cells by inducing the expression of topoisomerase IIα. , 2012, Molecular medicine reports.

[23]  I. Lossos,et al.  Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. , 2012, Blood.

[24]  J. Zuo,et al.  Crosstalk between Raf/MEK/ERK and PI3K/AKT in suppression of Bax conformational change by Grp75 under glucose deprivation conditions. , 2011, Journal of molecular biology.

[25]  P. Boffetta.  I. Epidemiology of adult non-Hodgkin lymphoma , 2011 .

[26]  J. Zuo,et al.  Glucose-regulated protein 75 suppresses apoptosis induced by glucose deprivation in PC12 cells through inhibition of Bax conformational change. , 2008, Acta biochimica et biophysica Sinica.

[27]  M. Czuczman,et al.  Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression , 2008, Clinical Cancer Research.

[28]  S. Kaul,et al.  Three faces of mortalin: A housekeeper, guardian and killer , 2007, Experimental Gerontology.

[29]  P. Várnai,et al.  Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels , 2006, The Journal of cell biology.

[30]  B. Bonavida,et al.  Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis , 2005, Oncogene.

[31]  M. Berridge,et al.  Calcium: Calcium signalling: dynamics, homeostasis and remodelling , 2003, Nature Reviews Molecular Cell Biology.

[32]  R. Reddel,et al.  Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. , 2000, Cancer research.

[33]  J. R. Smith,et al.  Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. , 2000, Biochemical and biophysical research communications.

[34]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[35]  S. Kaul,et al.  Elevated levels of mortalin expression in human brain tumors. , 1997, Experimental cell research.

[36]  A. Azem,et al.  Sequential action of two hsp70 complexes during protein import into mitochondria , 1997, The EMBO journal.

[37]  D. Longo,et al.  Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. , 1990, Journal of the National Cancer Institute.

[38]  M. Minden,et al.  The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. , 1987, Blood.

[39]  F. Appelbaum,et al.  Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.

[40]  S. Barta,et al.  2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management , 2021, American Journal of Hematology.

[41]  W. Chan,et al.  Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. , 2008, Blood.

[42]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[43]  T. Murata,et al.  Ca2+ administration stimulates the binding of AP-1 factor to the 5'-flanking region of the rat gene for the Ca2+-binding protein regucalcin. , 1998, The Biochemical journal.